Bronchiolitis is a common lower respiratory disease typically affecting infants and children
generally younger than 2 years of age. The disease leads to hospital admissions, is a major
cause for hospitalisation of young children and infants during winter epidemics, may be
severe sometimes requiring ventilatory support and rarely death. The clinical disease as
described by Court is characterised by nasal flaring, tachypnoea, dyspnoea, chest recessions,
crepitations and sometimes sibiliations. Respiratory Syncytial virus is the most common
cause, but also other respiratory vira may cause the disease. Bronchiolitis is a well known
risk factor of asthma development in childhood1,2.
Management is generally supportive, whereas symptom reducing therapy is debated with no
international consensus. Furthermore, there are many unresolved questions related to the
prognosis of bronchiolitis, its role in development of chronic lung disease in particular
regarding the association between early bronchiolitis and asthma development. The present
project will particularly focus on: 1)Treatment efficacy related to various outcomes during
active disease, 2) retrospectively assess treatment efficacy in relation to later development
of allergic disease, 3) assess the role between different vira and asthma prognosis as well
as 4) identify possible prognostic factors involved in the progression from bronchiolitis to
further airways disease.
Phase:
Phase 4
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Haukeland University Hospital Ostfold University College Ostfold University College, Fredrikstad, Norway Sorlandet Hospital HF Sykehuset i Vestfold HF Sykehuset Innlandet HF Sykehuset Telemark University of Oslo Vestre Viken Hospital Trust